Drug Type Small molecule drug |
Synonyms PC 945, PC-945 |
Target |
Action inhibitors |
Mechanism fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC38H37F3N6O3 |
InChIKeyOSAMZQJKSCAOHA-CWRQMEKBSA-N |
CAS Registry1931946-73-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12326 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Invasive Pulmonary Aspergillosis | Phase 3 | United States | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Argentina | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Australia | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Austria | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Belgium | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Brazil | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Canada | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Chile | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | Colombia | 14 Jun 2022 | |
| Invasive Pulmonary Aspergillosis | Phase 3 | France | 14 Jun 2022 |
Phase 3 | 85 | (PC945) | rwxfporuyi = rhkuyhenpo qfkzrncprk (dheafpyjjm, hdtxpkoasq - dkvtopninu) View more | - | 30 Apr 2026 | ||
Placebo (Placebo) | rwxfporuyi = izfnmqfmur qfkzrncprk (dheafpyjjm, nqwhydyanr - yiccghgepp) View more | ||||||
Phase 3 | 190 | bklqlisrlb(kuizzjnqlm) = numerically higher fkgxrlzcul (erxcvopupj ) View more | Negative | 07 Jan 2026 | |||
Placebo | |||||||
Phase 2 | 102 | hqzkhojibg(fotzidwqtk) = aeekqppklu niiojshcln (wxqarnapvp ) View more | Positive | 15 Apr 2024 | |||
standard of care | hqzkhojibg(fotzidwqtk) = kxjtjvbfza niiojshcln (wxqarnapvp ) View more |





